Payment overview · 2025
General Payments
$860.10
39 reported records · 18 companies
Healthcare provider profile · identity verified
David D. Deatkine, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BIRMINGHAM, AL · NPI 1336255850
Verified facts
What the public records show
CMS Open Payments records show David D. Deatkine, MD received $860.10 in general payments during 2025 across 39 reported records.
Novo Nordisk Inc accounted for 21.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Jatenzo, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Viberzi by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Ozempic by this doctor in 2024.
TOLMAR, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JATENZO as an associated drug or biological on 9766 records involving 5555 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jatenzo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $182.43 | 21.2% | 4 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $103.07 | 12.0% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $77.83 | 9.1% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $61.93 | 7.2% | 4 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $54.35 | 6.3% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $53.92 | 6.3% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.62 | 6.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.87 | 4.6% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $35.85 | 4.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $29.29 | 3.4% | 2 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $27.85 | 3.2% | 2 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $27.70 | 3.2% | 1 | 2025 |
| GC Biopharma USA, Inc. | Unresolved — no canonical attribution shown | $24.47 | 2.9% | 1 | 2025 |
| Rhythm Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.58 | 2.7% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $17.06 | 2.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.61 | 1.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.49 | 1.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.18 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $860.10 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $182.43 | 4 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $103.07 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $77.83 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $65.30 | 3 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $54.35 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $53.92 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.46 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $35.85 | 2 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $31.66 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $29.29 | 2 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $27.85 | 2 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $27.70 | 1 | 2025 |
Source payment records
|
|||||
| ALYGLO Normalized: alyglo |
Drug | GC Biopharma USA, Inc. | $24.47 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.40 | 1 | 2025 |
Source payment records
|
|||||
| IMCIVREE Normalized: imcivree |
Drug | Rhythm Pharmaceuticals, Inc. | $23.58 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.96 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 107 | exact normalized | Medicare Part D |
| JATENZO jatenzo |
2025 | Jatenzo | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 148 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
76 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
148 | 23 |
| TOLMAR, INC. Exact reporting entity; no affiliate inference |
2025 | JATENZO open payments reported associated product |
CMS Open Payments — General Payments 9766 supporting records · 5555 recipient NPIs · example record 1237000415 |
Jatenzo · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 306 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 268 | 79 |
| Ozempic | Semaglutide | 148 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 141 | 40 |
| Estradiol | Estradiol | 122 | 37 |
| Jardiance | Empagliflozin | 107 | 20 |
| Ezetimibe | Ezetimibe | 106 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 106 | 25 |
| Atorvastatin Calcium | Atorvastatin Calcium | 105 | 31 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 97 | 12 |
| Clonazepam | Clonazepam | 96 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 95 | 33 |
| Omeprazole | Omeprazole | 91 | 24 |
| Losartan Potassium | Losartan Potassium | 88 | 25 |
| Irbesartan | Irbesartan | 79 | 19 |
| Repatha Sureclick | Evolocumab | 76 | 15 |
| Synthroid | Levothyroxine Sodium | 76 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 74 | 21 |
| Trazodone Hcl | Trazodone Hcl | 74 | 22 |
| Carvedilol | Carvedilol | 72 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 22 |
| Gabapentin | Gabapentin | 72 | 22 |
| Tramadol Hcl | Tramadol Hcl | 71 | 20 |
| Alprazolam | Alprazolam | 70 | 20 |
| Eliquis | Apixaban | 67 | 14 |
| Meloxicam | Meloxicam | 67 | 22 |
| Metformin Hcl | Metformin Hcl | 67 | 20 |
| Progesterone | Progesterone, Micronized | 67 | 17 |
| Cefuroxime | Cefuroxime Axetil | 62 | 55 |
| Methocarbamol | Methocarbamol | 61 | 25 |
| Lisinopril | Lisinopril | 57 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 56 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 55 | 17 |
| Azithromycin | Azithromycin | 53 | 45 |
| Methylprednisolone | Methylprednisolone | 53 | 46 |
| Montelukast Sodium | Montelukast Sodium | 52 | 14 |
| Simvastatin | Simvastatin | 51 | 15 |
| Allopurinol | Allopurinol | 47 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 16 |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 28 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 25 |
| Celecoxib | Celecoxib | 39 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 38 | 15 |
| Furosemide | Furosemide | 37 | 17 |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 23 |
| Januvia | Sitagliptin Phosphate | 35 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | suppressed |
| Fluconazole | Fluconazole | 33 | 12 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Testosterone | Testosterone | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Creon | Lipase/Protease/Amylase | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | 11 |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 20 |
| Ondansetron Odt | Ondansetron | 23 | 17 |
| Valsartan | Valsartan | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Praluent Pen | Alirocumab | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Clonidine | Clonidine | 21 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Dotti | Estradiol | 16 | suppressed |
| Famciclovir | Famciclovir | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Triazolam | Triazolam | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 12 |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Clarithromycin | Clarithromycin | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Lorazepam | Lorazepam | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 11 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Jatenzo | Testosterone Undecanoate | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Viberzi | Eluxadoline | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $860.10 · 39 records | Novo Nordisk Inc | ALYGLO, Cologuard Collection Kit, EVENITY, GVOKE HYPOPEN, Hizentra, IMCIVREE, JARDIANCE, JATENZO, Korlym, LEQVIO, MOUNJARO, NEXLETOL, NP Thyroid 60, Ozempic, PRECIVITYAD2, RECORLEV, REPATHA, Rybelsus, TWIIST, UBRELVY, XIFAXAN, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error